To study the effect of rabeprolol combined with nimodipine for treating pregnant women with pregnancy induced hypertension, and to study its influence on their levels of serum pregnancy-associated plasma protein A (PAPPA), placental growth factor (PLGF), FIT-1. Methods: 82 women with pregnancy induced hypertension were collected and divided into observation group and control group (41 women in each group) according to the random number table from February 2016 to February 2018. The women in the control group were treated with nimodipine for 4 weeks, while the women in the observation group were treated with rabeprolol combined with nimodipine during the same time for 4 weeks. The blood pressure control situation, the levels of serum PAPPA, PLGF, and FIT-1, pregnancy outcomes, delivery mode, and adverse reactions rate of women were compared between the two groups. Results: After treatment, systolic blood pressure and diastolic blood pressure values had improved significantly, and the improvement degree of women in the observation group was significant better than that of women in the control group. The serum PAPPA level of women in the two groups had decreased significantly, PLGF and FIT-1 levels of women in the two groups had increased significantly, and the improvement degree of women in the observation group was significant better than that of women in the control group. In the observation group, the rate of natural childbirth (85.4%) of women in the observation group was significant higher than that (65.9%) of women in the control group, but the incidence of adverse pregnancy outcome (7.3%) of women in the observation group was significant lower than that (46.3%) of women in the control group (all P＜0.05). Conclusion: Abeprolol combined with nimodipine for treating pregnant women with pregnancy induced hypertension can increase the efficacy, which play a pharmacodynamic role by down-regulating serum PAPPA level and up-regulating the levels of PLGF and FIT-1.